Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • death

    Tag: death

    You Searched For "death"
    Pfizer gets USFDA approval for Vyndaqel, Vyndamax to treat amyloidosis cardiomyopathy

    Pfizer gets USFDA approval for Vyndaqel, Vyndamax to treat amyloidosis cardiomyopathy

    Farhat Nasim11 May 2019 9:15 AM IST
    New Delhi: Pfizer Inc's subsidiary FoldRx, has recently won U.S. Food and Drug Administration (USFDA) approved for Vyndaqel (tafamidis meglumine) and...
    Philippine lawyers sue Sanofi over dengue vaccine

    Philippine lawyers sue Sanofi over dengue vaccine

    Ruby Khatun Khatun9 Feb 2018 9:30 AM IST
    MANILA: A Philippine government agency filed a lawsuit against French drugmaker Sanofi demanding compensation for the parents of a 10-year-old girl...
    Trouble mounts for ELDER Pharma with the passing of MD

    Trouble mounts for ELDER Pharma with the passing of MD

    Ruby Khatun Khatun26 Oct 2017 5:35 PM IST
    MUMBAI: The demise of the Managing Director and Chief Executive Officer Alok Saxena of Elder Pharmaceuticals recently has indeed brought more trouble...
    Bristols drug cocktail cuts kidney cancer death risk 37 percent

    Bristols drug cocktail cuts kidney cancer death risk 37 percent

    Ruby Khatun Khatun14 Sept 2017 9:25 AM IST
    MADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
    Pharma Doyen, Lupin founder passes away

    Pharma Doyen, Lupin founder passes away

    Ruby Khatun Khatun27 Jun 2017 3:03 PM IST
    Mumbai: Dr Desh Bandhu Gupta, Founder and Chairman of Lupin Limited (Lupin), passed away early this morning in Mumbai. He was 79 years old. He will be...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok